



Clinical case

Cristina Suarez MD PhD
GU, CNS and Sarcomas Unit
Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology
Barcelona



DECLARATION OF INTERESTS

- ☐ Employment: None
- ☐ Consultant or Advisory Role: BMS, Eisai, Ipsen, MSD, Recordati, Telix
- ☐ Stock Ownership: None
- ☐ Research Funding: Ipsen, BMS, Pfizer, MSD
- ☐ Speaking: Ipsen, Eisai, MSD, Telix
- ☐ Travel/accommodation expenses: Ipsen, MSD, Recordati

CLINICAL CASE

♂ 62 years old
Dyslipemia, NO smoker
No other relevant medical history

Localized RCC

Metastatic RCC

May 2011



- **First symptom:** lumbar pain
- **Abdominal US:** Lesion in upper pole of right kidney
- **Uro-CT:** Right renal mass 11x8cm, no metastases. cT3N0M0
- **Blood test:** Hb 15g/dL, ANC 3.3 x10E9/L, PLT 327 x10E9/L, Calcium 9.5 mg/dL, Cr 0.71 mg/dL



Right radical nephrectomy

IQx in July 2011

Clear-Cell Renal Cell Carcinoma
pT3aN0M0



Resected nasal polyps:
M1 of RCC



NOV.12

Resected pancreatic lesion
M1 of RCC



OCT.15

Resected left maxillary lesion
M1 of RCC



OCT.16

Resected intradural lesion - L5
M1 of RCC



MAR.17

Pancreatic and retroperitoneal M1 of RCC



OCT.17

IQx

IQx

IQx

IQx

KEYNOTE-426

PD to M1

SBRT 36Gy

IMDC score: intermediate risk (anemia ; *retrospectively)

Nov.12

Oct.15

Oct.16

Mar.17

Oct.17

CLINICAL CASE

♂ 62 years old
Dyslipemia, NO smoker
No other relevant medical history

Localized RCC

Metastatic RCC

May 2011

- **First symptom:** lumbar pain
- **Abdominal US:** Lesion in upper pole of right kidney
- **Uro-CT:** Right renal mass 11x8cm, no metastases. cT3N0M0
- **Blood test:** Hb 15g/dL, ANC 3.3 x10E9/L, PLT 327 x10E9/L, Calcium 9.5 mg/dL, Cr 0.71 mg/dL



Right radical nephrectomy

IQx in July 2011

Clear-Cell Renal Cell Carcinoma
pT3aN0M0




Pancreatic and retroperitoneal M1

OCT.17



BOR: CR

FEB.20



Resected gastric polyp
Endoscopy polypectomy

M1 of RCC

JUN.24

May 2026

Last FU
MAR.2026

CR

KEYNOTE-426: PEMBROLIZUMAB 200mg IV q3w per 2y + AXITINIB 5mg BID

IMDC score: intermediate risk (anemia)

C1D1 DIC.2017 - C35D1 DIC.2019 (Pembrolizumab) ; Axitinib STOP on JUN.2022 due proteinuria

SECOND COURSE: C1D1 JUN.2024 - C35D1 JUN.2025 (Pembrolizumab)

Oct.17

Oct.20

Jun.24

Mar.26